PR Newswire
19 Oct 2023, 15:10 GMT+10
![]() |
SEOUL, South Korea, Oct. 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is thrilled to announce its participation in CPHI Worldwide 2023, one of the world's premier pharmaceutical industry exhibitions. The event is scheduled to take place from the 24th to the 26th of October at Fira Barcelona Gran Via, Spain.
Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market.
Daewoong Pharmaceutical will be prominently featured at Booth 80G30, Hall 8, where the company will present its extensive portfolio of pharmaceutical products, ranging from cutting-edge research and development to finished pharmaceuticals covering various therapeutic areas, including gastroenterology, metabolic, aesthetic, immunology, pain management, autoimmune and rare diseases.
CEO Sengho Jeon expressed his excitement about the event, stating, "We are eagerly anticipating the opportunity to connect with our global partners, explore potential collaborations, and engage in ongoing discussions, with the expectation of entering into additional agreements this year. Our aim is to discuss how we can make our world healthier together, and foster new business prospects through this exhibition."
Especially, Daewoong Pharmaceutical will accelerate to build partnership with global partner for their own novel drug such as GERD treatment (ingredient: Fexuprazan) and Diabetes treatment (ingredient: Enavogliflozin). As of now, Fexuprazan has successfully completed product registration applications in a total of 12 countries, including China, Mexico, Brazil, Saudi Arabia, and Indonesia. Additionally, the company has entered into technology export agreements with 18 countries, including China, further solidifying its global reach. Furthermore, Enavogliflozin, Daewoong Pharmaceutical's diabetes treatment, applied for product registration in Saudi Arabia, achieving an impressive expansion into five countries, including Indonesia, Thailand, the Philippines, and Vietnam.
Forward-Looking Statements
This press release contains forward-looking statements that are based on the current beliefs and expectations of Daewoong Pharmaceutical's management. Factors that could cause or contribute to such differences include, but are not limited to: (1) Regulatory and governmental approvals: The approval process for pharmaceutical products is subject to extensive regulations and may involve uncertainties and delays. Any failure to obtain necessary approvals or the occurrence of delays in the approval process could adversely affect Daewoong Pharmaceutical's business and results of operations; and (2) Clinical trials: The success of Daewoong Pharmaceutical's products depends on the results of clinical trials. The results of early clinical trials may not be indicative of the results of later-stage or larger-scale clinical trials.
Get a daily dose of Asia Bulletin news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Bulletin.
More InformationNEW YORK, New York - The U.S. was alone on Friday in a 13-1 vote for a ceasefire in the ...
WASHINGTON D.C.: The Associated Press (AP) reported that Manuel Rocha, a former American diplomat who served as U.S. ambassador to ...
MADISON, Wisconsin: On November 30, Hridindu Sankar Roychowdhury from Wisconsin pleaded guilty to firebombing a conservative anti-abortion group's office on ...
An Israeli tank crew killed a Reuters journalist and wounded six reporters in Lebanon on Oct. 13 by firing two ...
WASHINGTON DC - In a major blow to U.S. President Joe Biden, less that a year out from the November ...
TOKYO, Japan: This week, the U.S. Air Force said that divers have discovered the wreckage and the remains of five ...
WASHINGTON D.C.: To fix issues that could lead to further bank failures in the U.S., such as the collapse of ...
ARLINGTON, Virginia: This week, Reuters reported that Boeing delivered 46 narrowbody 737s jets in November. The total brings the U.S. ...
NEW YORK, New York - A positive employment report from the U.S. Bureau of Labor Statistics indicating a fall in ...
DALLAS, Texas: This week, AT&T said that by late 2026, it will use open radio access network (ORAN) technology for ...
NEW YORK: This week, ratings agency Moody's warned that it could downgrade China's credit rating, citing costs to bail out ...
NEW YORK, New York - AI set the scene for solid gains in technology shares on Thursday. Demand for Alphabet ...